5.18 USD
-0.24 (-4.43%)
5.1192 USD
-0.06 (-1.17%)
We assign a fundamental rating of 5 out of 10 to ORGO. ORGO was compared to 533 industry peers in the Biotechnology industry. ORGO has only an average score on both its financial health and profitability. ORGO has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
ORGO had positive earnings in the past year.
ORGO had a negative operating cash flow in the past year.
Of the past 5 years ORGO 4 years were profitable.
ORGO had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of ORGO (-2.63%) is better than 88.37% of its industry peers.
ORGO's Return On Equity of -3.47% is amongst the best of the industry. ORGO outperforms 90.24% of its industry peers.
ORGO's Return On Invested Capital of 0.16% is amongst the best of the industry. ORGO outperforms 89.12% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ORGO is significantly below the industry average of 18.83%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.63% | ||
| ROE | -3.47% | ||
| ROIC | 0.16% |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
1.3 Margins
The Operating Margin of ORGO (0.18%) is better than 89.31% of its industry peers.
In the last couple of years the Operating Margin of ORGO has declined.
ORGO's Gross Margin of 74.49% is amongst the best of the industry. ORGO outperforms 82.93% of its industry peers.
In the last couple of years the Gross Margin of ORGO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.18% | ||
| PM (TTM) | N/A | ||
| GM | 74.49% |
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
2. Health
2.1 Basic Checks
ORGO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for ORGO has been reduced compared to 1 year ago.
ORGO has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ORGO has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 4.61 indicates that ORGO is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.61, ORGO is in the better half of the industry, outperforming 73.73% of the companies in the same industry.
ORGO has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
ORGO has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: ORGO outperforms 46.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.61 |
ROIC/WACC0.02
WACC8.79%
2.3 Liquidity
A Current Ratio of 3.32 indicates that ORGO has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.32, ORGO is doing worse than 60.04% of the companies in the same industry.
A Quick Ratio of 2.88 indicates that ORGO has no problem at all paying its short term obligations.
ORGO's Quick ratio of 2.88 is on the low side compared to the rest of the industry. ORGO is outperformed by 63.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.32 | ||
| Quick Ratio | 2.88 |
3. Growth
3.1 Past
The earnings per share for ORGO have decreased strongly by -90.91% in the last year.
Measured over the past years, ORGO shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -37.90% on average per year.
The Revenue has been growing slightly by 2.24% in the past year.
Measured over the past years, ORGO shows a quite strong growth in Revenue. The Revenue has been growing by 13.05% on average per year.
EPS 1Y (TTM)-90.91%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)2.24%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%30.98%
3.2 Future
The Earnings Per Share is expected to grow by 46.59% on average over the next years. This is a very strong growth
Based on estimates for the next years, ORGO will show a quite strong growth in Revenue. The Revenue will grow by 12.92% on average per year.
EPS Next Y-136%
EPS Next 2Y36.38%
EPS Next 3Y46.59%
EPS Next 5YN/A
Revenue Next Year4.04%
Revenue Next 2Y14.25%
Revenue Next 3Y12.92%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ORGO is valuated quite expensively with a Price/Earnings ratio of 518.00.
88.37% of the companies in the same industry are more expensive than ORGO, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of ORGO to the average of the S&P500 Index (26.31), we can say ORGO is valued expensively.
With a Price/Forward Earnings ratio of 16.38, ORGO is valued correctly.
94.75% of the companies in the same industry are more expensive than ORGO, based on the Price/Forward Earnings ratio.
ORGO's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 36.59.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 518 | ||
| Fwd PE | 16.38 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ORGO indicates a rather cheap valuation: ORGO is cheaper than 91.74% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 32.94 |
4.3 Compensation for Growth
The decent profitability rating of ORGO may justify a higher PE ratio.
ORGO's earnings are expected to grow with 46.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.38%
EPS Next 3Y46.59%
5. Dividend
5.1 Amount
No dividends for ORGO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5.18
-0.24 (-4.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners55.08%
Inst Owner Change-1.32%
Ins Owners31.49%
Ins Owner Change0.22%
Market Cap657.13M
Revenue(TTM)465.22M
Net Income(TTM)-13.39M
Analysts85
Price Target8.16 (57.53%)
Short Float %15.79%
Short Ratio6.89
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)47.19%
Min EPS beat(2)-73%
Max EPS beat(2)167.38%
EPS beat(4)2
Avg EPS beat(4)147.99%
Min EPS beat(4)-73%
Max EPS beat(4)570.59%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.03%
Min Revenue beat(2)-4.23%
Max Revenue beat(2)10.3%
Revenue beat(4)2
Avg Revenue beat(4)3.25%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)13.3%
Revenue beat(8)5
Avg Revenue beat(8)2.23%
Revenue beat(12)6
Avg Revenue beat(12)1.36%
Revenue beat(16)7
Avg Revenue beat(16)0.62%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)12.9%
EPS NQ rev (3m)2.94%
EPS NY rev (1m)0%
EPS NY rev (3m)-200%
Revenue NQ rev (1m)2.46%
Revenue NQ rev (3m)1.4%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 518 | ||
| Fwd PE | 16.38 | ||
| P/S | 1.41 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.7 | ||
| P/tB | 1.89 | ||
| EV/EBITDA | 32.94 |
EPS(TTM)0.01
EY0.19%
EPS(NY)0.32
Fwd EY6.1%
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS3.67
BVpS3.04
TBVpS2.74
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.63% | ||
| ROE | -3.47% | ||
| ROCE | 0.2% | ||
| ROIC | 0.16% | ||
| ROICexc | 0.19% | ||
| ROICexgc | 0.21% | ||
| OM | 0.18% | ||
| PM (TTM) | N/A | ||
| GM | 74.49% | ||
| FCFM | N/A |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
ROICexc(3y)5.35%
ROICexc(5y)10.84%
ROICexgc(3y)6.4%
ROICexgc(5y)14.92%
ROCE(3y)4.79%
ROCE(5y)9.27%
ROICexgc growth 3Y-38.4%
ROICexgc growth 5YN/A
ROICexc growth 3Y-36.47%
ROICexc growth 5YN/A
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
F-Score2
Asset Turnover0.91
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.11 | ||
| Cap/Depr | 70.73% | ||
| Cap/Sales | 2.76% | ||
| Interest Coverage | 0.99 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.32 | ||
| Quick Ratio | 2.88 | ||
| Altman-Z | 4.61 |
F-Score2
WACC8.79%
ROIC/WACC0.02
Cap/Depr(3y)177.81%
Cap/Depr(5y)208.05%
Cap/Sales(3y)5.07%
Cap/Sales(5y)5.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-90.91%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y-136%
EPS Next 2Y36.38%
EPS Next 3Y46.59%
EPS Next 5YN/A
Revenue 1Y (TTM)2.24%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%30.98%
Revenue Next Year4.04%
Revenue Next 2Y14.25%
Revenue Next 3Y12.92%
Revenue Next 5YN/A
EBIT growth 1Y-91.44%
EBIT growth 3Y-33.42%
EBIT growth 5YN/A
EBIT Next Year410.89%
EBIT Next 3Y109.75%
EBIT Next 5YN/A
FCF growth 1Y-1334.78%
FCF growth 3Y-48.6%
FCF growth 5YN/A
OCF growth 1Y-238.05%
OCF growth 3Y-38.8%
OCF growth 5YN/A
ORGANOGENESIS HOLDINGS INC / ORGO FAQ
Can you provide the ChartMill fundamental rating for ORGANOGENESIS HOLDINGS INC?
ChartMill assigns a fundamental rating of 5 / 10 to ORGO.
What is the valuation status for ORGO stock?
ChartMill assigns a valuation rating of 5 / 10 to ORGANOGENESIS HOLDINGS INC (ORGO). This can be considered as Fairly Valued.
How profitable is ORGANOGENESIS HOLDINGS INC (ORGO) stock?
ORGANOGENESIS HOLDINGS INC (ORGO) has a profitability rating of 6 / 10.
What is the valuation of ORGANOGENESIS HOLDINGS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for ORGANOGENESIS HOLDINGS INC (ORGO) is 518 and the Price/Book (PB) ratio is 1.7.
Can you provide the expected EPS growth for ORGO stock?
The Earnings per Share (EPS) of ORGANOGENESIS HOLDINGS INC (ORGO) is expected to decline by -136% in the next year.